FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Puissance Life Science Opportunities Fund VI		 2. Issuer Name and Ticker or Trading Symbol

Bellerophon Therapeutics, Inc. [ BLPH ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

950 THIRD AVENUE, FL 25		 3. Date of Earliest Transaction (MM/DD/YYYY)

5/21/2020
(Street)

NEW YORK, NY 10022
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 5/21/2020  A  1153846 A$13 1153846 D (1) 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Puissance Life Science Opportunities Fund VI
950 THIRD AVENUE
FL 25
NEW YORK, NY 10022
X

Puissance Capital Fund (GP) LLC
950 THIRD AVENUE
25TH FLOOR
NEW YORK, NY 10022
X

Puissance Capital Management LP
950 THIRD AVENUE, 25TH FLOOR
NEW YORK, NY 10022
X

Puissance Capital Management (GP) LLC
950 THIRD AVENUE
25TH FLOOR
NEW YORK, NY 10022
X

Wang Theodore T
C/O PUISSANCE CAPITAL MANAGEMENT LP
950 THIRD AVENUE, 25TH FLOOR
NEW YORK, NY 10022		XX
Signatures
Puissance Life Science Opportunities Fund VI, By: Puissance Capital Fund (GP) LLC, its managing member, By: Theodore T. Wang, Managing Member5/22/2020
**Signature of Reporting PersonDate

Puissance Capital Fund (GP) LLC, By: Theodore T. Wang, Managing Member5/22/2020
**Signature of Reporting PersonDate

Puissance Capital Management LP, By: Puissance Capital Management (GP) LLC, its general partner, By: Theodore T. Wang, Managing Member5/22/2020
**Signature of Reporting PersonDate

Puissance Capital Management (GP) LLC, By: Theodore Wang, Managing Member5/22/2020
**Signature of Reporting PersonDate

/s/ Theodore T. Wang5/22/2020
**Signature of Reporting PersonDate
Bellerophon Therapeutics (NASDAQ:BLPH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Bellerophon Therapeutics Charts.
Bellerophon Therapeutics (NASDAQ:BLPH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Bellerophon Therapeutics Charts.